^
    Apply
    Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelial Carcinoma (ETCTN 10183) (NCT03854474)
    Phase 1/2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/12/2025
    Initiation :
    11/18/2019
    Primary completion :
    06/30/2025
    Completion :
    06/30/2025
    PD-L1 • PD-1
    |
    EZH2 mutation
    |
    Keytruda (pembrolizumab) • cisplatin • Tazverik (tazemetostat) • Pembroria (pembrolizumab biosimilar)
    CPI-0209 Plus Carboplatin in Patients With Platinum Sensitive Recurrent Ovarian Cancer (NCT05942300)
    Phase 1
    Lan Coffman
    Recruiting
    Last update posted :
    02/11/2025
    Initiation :
    01/10/2024
    Primary completion :
    05/31/2025
    Completion :
    08/31/2028
    BRCA
    |
    BRCA mutation
    |
    carboplatin • tulmimetostat (DZR123)
    Phase 1b Study of EZH1/2 Inhibitor Valemetostat in Combination With Trastuzumab Deruxtecan in Subjects With HER2 Low/Ultra-low/Null Metastatic Breast Cancer (NCT05633979)
    Phase 1
    M.D. Anderson Cancer Center
    Recruiting
    Last update posted :
    02/10/2025
    Initiation :
    02/09/2023
    Primary completion :
    12/31/2030
    Completion :
    12/31/2032
    HER-2 • UGT1A1
    |
    Enhertu (fam-trastuzumab deruxtecan-nxki) • Ezharmia (valemetostat)
    Testing of Tazemetostat in Combination With Topotecan and Pembrolizumab in Patients With Recurrent Small Cell Lung Cancer (NCI-2022-03215) (NCT05353439)
    Phase 1
    National Cancer Institute (NCI)
    Suspended
    Last update posted :
    01/28/2025
    Initiation :
    07/27/2022
    Primary completion :
    04/01/2025
    Completion :
    04/01/2025
    CD4
    |
    Keytruda (pembrolizumab) • Tazverik (tazemetostat) • topotecan • Pembroria (pembrolizumab biosimilar)
    Study of Valemetostat Tosylate as a Single Agent in Patients With Relapse/Refractory B-cell Lymphoma (VALYM) (NCT04842877)
    Phase 2
    The Lymphoma Academic Research Organisation
    Active, not recruiting
    Last update posted :
    01/24/2025
    Initiation :
    06/11/2021
    Primary completion :
    12/03/2024
    Completion :
    10/01/2026
    SLC1A5
    |
    EZH2 mutation
    |
    Ezharmia (valemetostat)
    A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations (KEYNOTE-F85) (NCT06644768)
    Phase 1/2
    Daiichi Sankyo
    Recruiting
    Last update posted :
    11/14/2024
    Initiation :
    10/30/2024
    Primary completion :
    03/30/2028
    Completion :
    04/30/2030
    PD-L1
    |
    Keytruda (pembrolizumab) • Ezharmia (valemetostat)
    Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors (TAZNI) (NCT05407441)
    Phase 1/2
    Susan Chi, MD
    Recruiting
    Last update posted :
    09/13/2024
    Initiation :
    08/10/2023
    Primary completion :
    02/01/2027
    Completion :
    02/01/2029
    SMARCB1
    |
    SMARCA4 mutation
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • Tazverik (tazemetostat)
    A Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas (FIH) (NCT04104776)
    Phase 1/2
    Constellation Pharmaceuticals
    Recruiting
    Last update posted :
    08/02/2024
    Initiation :
    09/18/2019
    Primary completion :
    12/31/2025
    Completion :
    03/01/2026
    MSI • ARID1A • BAP1
    |
    MSI-H/dMMR • ARID1A mutation
    |
    irinotecan • tulmimetostat (DZR123)
    Study of Tazemetostat Versus Placebo When Given in Combination With Lenalidomide and Rituximab in Participants With Relapsed/Refractory Follicular Lymphoma (SYMPHONY-1) (NCT04224493)
    Phase 3
    Epizyme, Inc.
    Recruiting
    Last update posted :
    06/13/2024
    Initiation :
    06/11/2020
    Primary completion :
    03/01/2026
    Completion :
    03/01/2029
    EZH2
    |
    EZH2 mutation
    |
    Rituxan (rituximab) • lenalidomide • Tazverik (tazemetostat)
    A Study to Assess Efficacy and Safety of Oral Tazemetostat in Adult Participants With Relapsed/Refractory Follicular Lymphoma That Does Not Have an "EZH2 Gain-of-function" Genetic Mutation (Mandolin) (NCT06068881)
    Phase 2
    Epizyme, Inc.
    Not yet recruiting
    Last update posted :
    06/03/2024
    Initiation :
    09/02/2024
    Primary completion :
    09/28/2027
    Completion :
    09/28/2027
    EZH2
    |
    EZH2 mutation • EZH2 wild-type
    |
    Tazverik (tazemetostat)
    A Study of Tazemetostat With Enzalutamide or Abiraterone/Prednisone in Participants With Advanced Prostate Cancer (CELLO-1) (NCT04179864)
    Phase 1/2
    Epizyme, Inc.
    Active, not recruiting
    Last update posted :
    06/03/2024
    Initiation :
    11/18/2019
    Primary completion :
    06/28/2024
    Completion :
    06/28/2024
    EZH2
    |
    Xtandi (enzalutamide) • abiraterone acetate • prednisone • Tazverik (tazemetostat)
    DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers (NCT04388852)
    Phase 1
    M.D. Anderson Cancer Center
    Recruiting
    Last update posted :
    05/16/2024
    Initiation :
    08/20/2020
    Primary completion :
    12/31/2026
    Completion :
    12/31/2026
    PD-L1 • TP53 • PTEN • RB1
    |
    Yervoy (ipilimumab) • Ezharmia (valemetostat)
    Evaluate the Safety and Clinical Activity of HH2853 (NCT04390737)
    Phase 1/2
    Haihe Biopharma Co., Ltd.
    Recruiting
    Last update posted :
    05/09/2024
    Initiation :
    09/08/2020
    Primary completion :
    12/31/2025
    Completion :
    12/31/2025
    ARID1A • BAP1
    |
    ARID1A mutation • BAP1 mutation • EZH2 mutation • SMARCA4 mutation
    |
    HH2853
    A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (NCT05683171)
    Phase 1/2
    M.D. Anderson Cancer Center
    Recruiting
    Last update posted :
    05/09/2024
    Initiation :
    05/19/2023
    Primary completion :
    09/30/2025
    Completion :
    09/30/2025
    UGT1A1
    |
    UGT1A1*1*1 • UGT1A1 mutation
    |
    Rituxan (rituximab) • lenalidomide • Ezharmia (valemetostat)
    Study of Tazemetostat in Lymphoid Malignancies (NCT05983965)
    Phase 1
    University of Alabama at Birmingham
    Not yet recruiting
    Last update posted :
    05/08/2024
    Initiation :
    08/01/2024
    Primary completion :
    06/01/2028
    Completion :
    12/01/2029
    CD4
    |
    Chr t(11;14) • CCND1 expression
    |
    Calquence (acalabrutinib) • Tazverik (tazemetostat)
    A Study of Tazemetostat in Adult Participants With Soft Tissue Sarcoma (NCT02601950)
    Phase 2
    Epizyme, Inc.
    Completed
    Last update posted :
    04/29/2024
    Initiation :
    12/22/2015
    Primary completion :
    02/26/2024
    Completion :
    02/26/2024
    CD34 • SS18
    |
    SMARCA4 mutation
    |
    Tazverik (tazemetostat)
    Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment (ETCTN 10500) (NCT05627245)
    Phase 1
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    04/15/2024
    Initiation :
    03/01/2023
    Primary completion :
    03/01/2025
    Completion :
    03/01/2025
    EZH2
    |
    RAS wild-type • EZH2 mutation • EZH2 wild-type
    |
    Tazverik (tazemetostat) • Beleodaq (belinostat)
    Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01) (NCT04703192)
    Phase 2
    Daiichi Sankyo
    Active, not recruiting
    Last update posted :
    04/12/2024
    Initiation :
    06/03/2021
    Primary completion :
    05/10/2023
    Completion :
    04/30/2028
    ALK • CD8
    |
    ALK positive • ALK negative
    |
    Ezharmia (valemetostat)
    Tazemetostat Expanded Access Program for Adults With Epithelioid Sarcoma (NCT04225429)
    Phase N/A
    Epizyme, Inc.
    No Longer Available
    Last update posted :
    03/22/2024
    CD34
    |
    Tazverik (tazemetostat)
    Palbociclib or Tazemetostat in Combination With CPX-351 for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (NCT05627232)
    Phase 1
    Thomas Jefferson University
    Recruiting
    Last update posted :
    01/05/2024
    Initiation :
    08/28/2023
    Primary completion :
    01/01/2026
    Completion :
    01/01/2026
    CASP3 • ANXA5
    |
    Ibrance (palbociclib) • Vyxeos (cytarabine/daunorubicin liposomal formulation) • Tazverik (tazemetostat)
    Phase Ⅰ/Ⅱ Study of SHR2554 in Combination With SHR1701 in Patients With Advanced Solid Tumors and B-cell Lymphomas (NCT04407741)
    Phase 1/2
    Chinese PLA General Hospital
    Recruiting
    Last update posted :
    12/12/2023
    Initiation :
    09/01/2020
    Primary completion :
    12/01/2024
    Completion :
    12/01/2025
    EGFR • BRAF • ALK • ROS1
    |
    retlirafusp alfa (SHR-1701) • SHR-2554
    Tazemetostat in Treating Patients With Recurrent Ovarian or Endometrial Cancer (NRG-GY014) (NCT03348631)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    11/08/2023
    Initiation :
    05/01/2019
    Primary completion :
    04/14/2023
    Completion :
    09/21/2024
    ARID1A
    |
    MSI-H/dMMR • ARID1A mutation
    |
    Tazverik (tazemetostat)
    Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize Effects of a Moderate CYP3A Inhibitor on PK of Tazemetostat, Effects of Tazemetostat on PK of CYP2C8 and CYP2C19 Substrates, and Effect of Increased Gastric pH on PK of Tazemetostat in B-cell Lymphoma or Advanced Solid Tumor Patients (NCT03028103)
    Phase 1
    Epizyme, Inc.
    Completed
    Last update posted :
    06/26/2023
    Initiation :
    03/27/2017
    Primary completion :
    10/31/2019
    Completion :
    11/29/2019
    SLC1A5
    |
    cisplatin • Tazverik (tazemetostat) • omeprazole
    Phase II Study of Tazemetostat in Solid Tumors Harboring an ARID1A Mutation (NCT05023655)
    Phase 2
    Prisma Health-Upstate
    Recruiting
    Last update posted :
    04/18/2023
    Initiation :
    01/06/2022
    Primary completion :
    01/01/2025
    Completion :
    01/01/2026
    ARID1A
    |
    ARID1A mutation
    |
    Tazverik (tazemetostat)
    Study of Tazemetostat in Newly Diagnosed Diffuse Large B Cell and Follicular Lymphoma Patients Treated by Chemiotherapy (Epi-RCHOP) (NCT02889523)
    Phase 1/2
    The Lymphoma Academic Research Organisation
    Active, not recruiting
    Last update posted :
    03/17/2023
    Initiation :
    10/01/2016
    Primary completion :
    01/31/2023
    Completion :
    04/01/2026
    CD20
    |
    CD20 positive
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • Tazverik (tazemetostat) • cyclophosphamide intravenous • prednisolone
    Combining Epigenetic And Immune Therapy to Beat Cancer. (CAIRE) (NCT04705818)
    Phase 2
    Institut Bergonié
    Recruiting
    Last update posted :
    03/01/2023
    Initiation :
    07/23/2021
    Primary completion :
    07/01/2023
    Completion :
    01/01/2025
    MSI • IFNG
    |
    IFNG expression
    |
    Imfinzi (durvalumab) • Tazverik (tazemetostat)
    ORIOn-E: A Study Evaluating CPI-1205 in Patients With Advanced Solid Tumors (NCT03525795)
    Phase 1
    Constellation Pharmaceuticals
    Completed
    Last update posted :
    05/18/2022
    Initiation :
    12/14/2017
    Primary completion :
    06/12/2019
    Completion :
    06/12/2019
    PD-L1
    |
    Yervoy (ipilimumab) • lirametostat (CPI-1205)
    A Phase 1 Study of SHR2554 in Subjects With Relapsed or Refractory Mature Lymphoid Neoplasms (NCT03603951)
    Phase 1
    Jiangsu HengRui Medicine Co., Ltd.
    Recruiting
    Last update posted :
    04/29/2022
    Initiation :
    08/14/2018
    Primary completion :
    02/14/2023
    Completion :
    08/14/2023
    BCL2 • BCL6
    |
    EZH2 mutation
    |
    SHR-2554
    A Phase 1 Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma (NCT02601937)
    Phase 1
    Epizyme, Inc.
    Completed
    Last update posted :
    12/27/2021
    Initiation :
    01/07/2016
    Primary completion :
    10/22/2021
    Completion :
    10/22/2021
    SS18
    |
    SMARCA4 mutation
    |
    Tazverik (tazemetostat)
    Study of the EZH2 Inhibitor Tazemetostat in Malignant Mesothelioma (NCT02860286)
    Phase 2
    Epizyme, Inc.
    Completed
    Last update posted :
    04/09/2021
    Initiation :
    07/01/2016
    Primary completion :
    06/01/2018
    Completion :
    05/01/2019
    BAP1
    |
    BAP1 mutation
    |
    Tazverik (tazemetostat)